health
Talazoparib Plus Enzalutamide Shows No Clear Extra Benefit in Prostate Cancer Trial
In a randomized phase 2 trial of 54 men with high-volume metastatic hormone-naive prostate cancer, talazoparib plus enzalutamide produced a high PSA response rate but no clear advantage over enzalutamide alone. Severe adverse events were more frequent with the combination, and two patients developed fatal acute myeloid leukaemia.